There are currently 118 active clinical trials seeking participants for Multiple Sclerosis research studies. The states with the highest number of trials for Multiple Sclerosis participants are Florida, New York, California and Texas.
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
Recruiting
The purpose of this research is to support the clinical value of the Cionic Neural Sleeve for individuals diagnosed with multiple sclerosis (MS).
Gender:
ALL
Ages:
Between 22 years and 75 years
Trial Updated:
03/19/2025
Locations: Cleveland State University, Cleveland, Ohio
Conditions: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Chronic Progressive
Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)
Recruiting
Studies performed under 89-N-0045 are designed to examine the natural history of multiple sclerosis (MS) using MRI and immunological measures. In addition to studying the natural history of untreated patients, the natural history of patients receiving approved disease-modifying therapies of MS will be examined. In both cohorts of patients levels of disease activity on MRI will be compared with immunological characteristics in order to help identify disease mechanism. Patients with either definit... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
05/31/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Multiple Sclerosis
Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System
Recruiting
Inflammatory or degenerative diseases of the brain and spinal cord, such as multiple sclerosis, may be related to problems with an individual s immune system. However, more information is needed on the ways in which the cells of the immune system interact with the central nervous system (CNS). This study will compare tests performed on both healthy volunteers and individuals who have signs or symptoms of immune-related damage to their CNS. This study will include two groups of subjects at least... Read More
Gender:
ALL
Ages:
Between 1 month and 99 years
Trial Updated:
05/31/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Central Nervous System Disease, Multiple Sclerosis
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
Recruiting
Background: In people with multiple sclerosis (MS), brain and cerebrospinal fluid (CSF) biomarkers indicate inflammation or disease. Researchers want to see if 4 drugs given alone or combined affect MS biomarkers. They want to see if a change in biomarker levels can predict which drugs a person with MS might respond to. Objective: To see if signs of inflammation in CSF help predict a person s response to different drugs. Eligibility: People ages 18 and older who: * Are in protocol 09-I-003... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
05/31/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Multiple Sclerosis
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Recruiting
The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to 36 months double-blind administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with nrSPMS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criter... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
05/30/2025
Locations: Alabama Neurology Associates- Site Number : 8400115, Birmingham, Alabama +298 locations
Conditions: Multiple Sclerosis
Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation
Recruiting
The study aims to compare the experiences, including injection-related reactions (IRRs) of patients newly receiving ofatumumab to those starting to receive ocrelizumab SC formulation
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
05/30/2025
Locations: Novartis Investigative site, East Hanover, New Jersey
Conditions: Multiple Sclerosis
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
Recruiting
The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: TG Therapeutics Investigational Trial Site, Birmingham, Alabama +57 locations
Conditions: Relapsing Multiple Sclerosis, Multiple Sclerosis
A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)
Recruiting
The primary objective of the study is to compare the prevalence rate of major congenital malformations (MCM) between 2 cohorts of pregnant participants with MS who are exposed to BRIUMVI® and who are unexposed to BRIUMVI®.
Gender:
FEMALE
Ages:
Between 15 years and 50 years
Trial Updated:
05/29/2025
Locations: BRIUMVI® Pregnancy Registry Virtual Research Coordination Center, Wilmington, North Carolina
Conditions: Multiple Sclerosis
Effects of High-intensity Gait Training on Fatigue, Gait, and Neuroplasticity in People With Multiple Sclerosis
Recruiting
Nearly 1 million individuals in the United States have multiple sclerosis, which causes fatigue and problems with walking. Fatigue and walking problems are poorly treated, but exercise training, particularly high-intensity walking exercise, may help. This provide insight into whether high-intensity walking exercise can improve fatigue and walking problems in people with multiple sclerosis, which could improve quality of life and reduce economic burden.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
05/27/2025
Locations: University of Illinois Chicago, Chicago, Illinois
Conditions: Multiple Sclerosis
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
Recruiting
The primary objective of this trial is to evaluate the safety and reactogenicity of mRNA-1195 in participants with multiple sclerosis.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
05/23/2025
Locations: ANESC Research, El Paso, Texas
Conditions: Multiple Sclerosis
ECoG BMI for Motor and Speech Control
Recruiting
Test the feasibility of using electrocorticography (ECoG) signals to control complex devices for motor and speech control in adults severely affected by neurological disorders.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: University of California San Francisco, San Francisco, California
Conditions: ALS, SCI - Spinal Cord Injury, Stroke, Multiple Sclerosis, Muscular Dystrophies
Prevalence and Impact of Obstructive Sleep Apnea in Multiple Sclerosis
Recruiting
This study will evaluate the influence of sleep apnea on clinical and radiological features of MS. Sleep apnea is associated with hypoxemia during sleep, which is likely detrimental to MS. Clinical data (MRI, lab results, medical history, labs, and sleep studies) of MS patients will be collected and analyzed. This will be done to study correlations between MRI, clinical data, lab studies and sleep studies. There is specific interest in the type of sleep apnea associated with MS, and whether MRI... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Multiple Sclerosis, Obstructive Sleep Apnea